About Medtronic (NYSE:MDT)
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio40.0445322390751
Forward P/E Ratio17.11
Sales & Book Value
Annual Sales$29.71 billion
Price / Sales3.71
Cash Flow$6.73 per share
Price / Cash12.08
Book Value$37.14 per share
Price / Book2.19
Net Income$4.03 billion
Return on Equity12.65%
Return on Assets6.58%
Medtronic (NYSE:MDT) Frequently Asked Questions
What is Medtronic's stock symbol?
Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."
How often does Medtronic pay dividends? What is the dividend yield for Medtronic?
Medtronic announced a quarterly dividend on Friday, March 9th. Investors of record on Friday, March 23rd will be paid a dividend of $0.46 per share on Friday, April 13th. This represents a $1.84 annualized dividend and a dividend yield of 2.26%. The ex-dividend date of this dividend is Thursday, March 22nd. View Medtronic's Dividend History.
How will Medtronic's stock buyback program work?
Medtronic declared that its board has initiated a share buyback program on Thursday, October 5th 2017, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 49% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board of directors believes its shares are undervalued.
How were Medtronic's earnings last quarter?
Medtronic plc. (NYSE:MDT) announced its quarterly earnings data on Tuesday, February, 20th. The medical technology company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.16 by $0.01. The medical technology company earned $7.37 billion during the quarter, compared to analyst estimates of $7.20 billion. Medtronic had a net margin of 9.44% and a return on equity of 12.65%. Medtronic's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 EPS. View Medtronic's Earnings History.
When will Medtronic make its next earnings announcement?
Where is Medtronic's stock going? Where will Medtronic's stock price be in 2018?
22 Wall Street analysts have issued 12 month target prices for Medtronic's stock. Their predictions range from $80.00 to $99.00. On average, they expect Medtronic's stock price to reach $91.31 in the next twelve months. View Analyst Ratings for Medtronic.
What are Wall Street analysts saying about Medtronic stock?
Here are some recent quotes from research analysts about Medtronic stock:
- 1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)
- 2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)
- 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
Who are some of Medtronic's key competitors?
Some companies that are related to Medtronic include UnitedHealth Group (UNH), Pfizer (PFE), Roche (RHHBY), Novartis (NVS), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), Stryker (SYK), Becton Dickinson and (BDX), Anthem (ANTM), Allergan (AGN), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX), Fresenius (FSNUY), Express Scripts (ESRX) and Takeda Pharmaceutical (TKPYY).
Who owns Medtronic stock?
Medtronic's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.99%), Franklin Resources Inc. (2.81%), Lazard Asset Management LLC (1.67%), Barrow Hanley Mewhinney & Strauss LLC (1.16%), Bank of New York Mellon Corp (1.06%) and Geode Capital Management LLC (1.05%). Company insiders that own Medtronic stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic.
Who sold Medtronic stock? Who is selling Medtronic stock?
Medtronic's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Barrow Hanley Mewhinney & Strauss LLC, PGGM Investments, Credit Agricole S A and King Luther Capital Management Corp. Company insiders that have sold Medtronic company stock in the last year include Bryan C Hanson, Carol A Surface, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.
Who bought Medtronic stock? Who is buying Medtronic stock?
Medtronic's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., HealthCor Management L.P., Rockefeller Financial Services Inc., Boston Partners, Vontobel Asset Management Inc., Mackenzie Financial Corp, The Manufacturers Life Insurance Company and Sterling Capital Management LLC. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.
How do I buy Medtronic stock?
Shares of Medtronic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medtronic's stock price today?
One share of Medtronic stock can currently be purchased for approximately $81.29.
How big of a company is Medtronic?
Medtronic has a market capitalization of $111.55 billion and generates $29.71 billion in revenue each year. The medical technology company earns $4.03 billion in net income (profit) each year or $2.03 on an earnings per share basis. Medtronic employs 91,000 workers across the globe.
How can I contact Medtronic?
Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]
MarketBeat Community Rating for Medtronic (MDT)MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Medtronic (NYSE:MDT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.68||2.64||2.57||2.57|
|Ratings Breakdown: ||0 Sell Rating(s)|
7 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
8 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
10 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
9 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$91.31||$90.86||$88.75||$88.82|
|Price Target Upside: ||12.32% upside||13.26% upside||9.20% upside||11.38% upside|
Medtronic (NYSE:MDT) Consensus Price Target History
Medtronic (NYSE:MDT) Analyst Ratings History
(Data available from 3/16/2016 forward)
Medtronic (NYSE:MDT) Earnings History and Estimates Chart
Medtronic (NYSE MDT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/20/2018||Q3 18||$1.16||$1.17||$7.20 billion||$7.37 billion||View||Listen|
|11/21/2017||Q2 18||$0.99||$1.07||$7.05 billion||$7.05 billion||View||N/A|
|8/22/2017||7/31/2017||$1.08||$1.12||$7.44 billion||$7.39 billion||View||N/A|
|5/25/2017||Q4 17||$1.31||$1.33||$7.86 billion||$7.92 billion||View||N/A|
|2/21/2017||1/31/2017||$1.11||$1.12||$7.22 billion||$7.28 billion||View||Listen|
|11/22/2016||Q217||$1.11||$1.12||$7.46 billion||$7.35 billion||View||Listen|
|8/25/2016||Q117||$1.01||$1.03||$7.17 billion||$7.20 billion||View||Listen|
|5/31/2016||Q416||$1.26||$1.27||$7.49 billion||$7.57 billion||View||Listen|
|3/1/2016||Q316||$1.06||$1.06||$6.99 billion||$6.93 billion||View||Listen|
|12/3/2015||Q216||$1.00||$1.03||$7.08 billion||$7.06 billion||View||Listen|
|9/3/2015||Q116||$1.01||$1.02||$7.03 billion||$7.27 billion||View||Listen|
|6/2/2015||Q415||$1.11||$1.16||$7.18 billion||$7.30 billion||View||Listen|
|2/17/2015||Q3||$0.97||$1.01||$4.25 million||$4.32 million||View||Listen|
|11/18/2014||Q2||$0.96||$0.96||$4.37 million||$4.40 million||View||Listen|
|8/19/2014||Q115||$0.92||$0.93||$4.25 billion||$4.27 billion||View||Listen|
|5/20/2014||Q414||$1.12||$1.12||$4.58 billion||$4.60 billion||View||Listen|
|2/18/2014||Q314||$0.91||$0.91||$4.15 billion||$4.20 billion||View||Listen|
|11/19/2013||Q214||$0.90||$0.91||$4.18 billion||$4.20 billion||View||Listen|
|8/20/2013||Q1 2014||$0.88||$0.88||$4.11 billion||$4.10 billion||View||Listen|
|5/21/2013||Q4 2013||$1.03||$1.10||$4.39 billion||$4.50 billion||View||Listen|
|2/19/2013||Q3 2013||$0.91||$0.93||$4.03 billion||$4.03 billion||View||Listen|
Medtronic (NYSE:MDT) Earnings Estimates
2018 EPS Consensus Estimate: $4.72
2019 EPS Consensus Estimate: $5.20
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Medtronic (NYSE:MDT) Dividend Information
|Dividend Growth:||15.00% (3 Year Average)|
|Payout Ratio:||90.64% (Trailing 12 Months of Earnings) |
38.74% (Based on This Year's Estimates)
35.73% (Based on Next Year's Estimates)
|Track Record:||40 Years of Consecutive Dividend Growth|
Medtronic (NYSE:MDT) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Medtronic (NYSE MDT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 80.79%
Medtronic (NYSE MDT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/13/2018||James T. Lenehan||Director||Sell||1,306||$83.56||$109,129.36|| |
|3/5/2018||Carol A Surface||SVP||Sell||24,479||$78.18||$1,913,768.22|| |
|1/9/2018||Richard Kuntz||VP||Sell||78,526||$86.21||$6,769,726.46||149,761|| |
|1/5/2018||Hooman Hakami||EVP||Sell||26,158||$85.00||$2,223,430.00|| |
|12/15/2017||Bryan C Hanson||EVP||Sell||16,000||$82.82||$1,325,120.00||88,818|| |
|11/16/2017||Bryan C. Hanson||EVP||Sell||16,000||$79.02||$1,264,320.00|| |
|10/16/2017||Bryan C Hanson||EVP||Sell||16,000||$78.03||$1,248,480.00|| |
|9/15/2017||Omar Ishrak||CEO||Sell||140,407||$81.63||$11,461,423.41||668,503|| |
|7/17/2017||Bryan C. Hanson||EVP||Sell||12,000||$88.57||$1,062,840.00|| |
|6/21/2017||Richard H Anderson||Director||Buy||5,600||$88.90||$497,840.00||71,910|| |
|3/20/2017||Hoedt Rob Ten||EVP||Sell||50,757||$81.58||$4,140,756.06||59,392|| |
|3/15/2017||Omar Ishrak||CEO||Sell||95,000||$82.82||$7,867,900.00||645,616|| |
|3/2/2017||Hooman Hakami||EVP||Sell||52,316||$82.33||$4,307,176.28||73,800|| |
|12/13/2016||Robert C. Pozen||Director||Buy||13,660||$73.21||$1,000,048.60|| |
|11/23/2016||James T. Lenehan||Director||Buy||2,000||$73.27||$146,540.00|| |
|9/27/2016||Richard Kuntz||VP||Sell||17,141||$86.70||$1,486,124.70||149,425|| |
|9/26/2016||Richard Kuntz||VP||Sell||25,199||$86.67||$2,183,997.33||149,425|| |
|9/15/2016||Kendall J. Powell||Director||Sell||7,907||$85.45||$675,653.15|| |
|9/15/2016||Omar Ishrak||CEO||Sell||61,925||$84.93||$5,259,290.25||565,916|| |
|8/29/2016||Bryan C Hanson||EVP||Sell||15,000||$87.00||$1,305,000.00||168,192|| |
|7/26/2016||Bryan C Hanson||EVP||Sell||15,000||$87.00||$1,305,000.00||108,717|| |
|7/15/2016||Geoffrey Martha||EVP||Sell||3,766||$88.26||$332,387.16|| |
|7/13/2016||Gary Lee Ellis||EVP||Sell||35,495||$88.64||$3,146,276.80|| |
|7/13/2016||Shirley A Jackson||Director||Sell||2,104||$88.64||$186,498.56||34,503|| |
|7/6/2016||Carol A. Surface||SVP||Sell||9,787||$87.08||$852,251.96|| |
|7/5/2016||Bryan C. Hanson||EVP||Sell||15,272||$87.11||$1,330,343.92|| |
|6/3/2016||Richard Kuntz||VP||Sell||49,905||$82.60||$4,122,153.00||127,647|| |
|4/1/2016||Richard Kuntz||VP||Sell||4,000||$75.22||$300,880.00||104,358|| |
|3/18/2016||Shirley A Jackson||Director||Sell||1,238||$75.60||$93,592.80||29,812|| |
|3/17/2016||Omar Ishrak||CEO||Sell||23,799||$76.15||$1,812,293.85||601,838|| |
|3/4/2016||Bryan C Hanson||EVP||Sell||5,000||$75.00||$375,000.00||96,806|| |
|2/5/2016||Bryan C. Hanson||EVP||Sell||5,000||$76.14||$380,700.00|| |
|1/8/2016||Bryan C Hanson||EVP||Sell||5,000||$75.00||$375,000.00||106,514|| |
|12/4/2015||Richard Kuntz||VP||Sell||13,715||$78.06||$1,070,592.90||108,086|| |
|9/15/2015||Omar Ishrak||CEO||Sell||20,000||$69.43||$1,388,600.00||526,824|| |
|7/14/2015||Carol A Surface||SVP||Sell||13,722||$75.83||$1,040,539.26|| |
|4/6/2015||Richard Kuntz||VP||Sell||31,768||$77.39||$2,458,525.52|| |
|3/25/2015||Gary Lee Ellis||CFO||Sell||43,183||$77.81||$3,360,069.23|| |
|3/13/2015||Omar Ishrak||CEO||Sell||20,000||$76.24||$1,524,800.00|| |
|2/19/2015||Christopher J Oconnell||EVP||Sell||50,361||$78.22||$3,939,237.42|| |
|12/19/2014||Richard Kuntz||VP||Sell||12,855||$74.54||$958,211.70|| |
|12/2/2014||Shirley A Jackson||Director||Sell||1,102||$74.43||$82,021.86|| |
|11/28/2014||Christopher J Oconnell||EVP||Sell||42,921||$73.95||$3,174,007.95|| |
|10/6/2014||Christopher J Oconnell||EVP||Sell||15,388||$64.98||$999,912.24|| |
|8/26/2014||Christopher J Oconnell||EVP||Sell||28,000||$63.57||$1,779,960.00|| |
|8/26/2014||Shirley A Jackson||Director||Sell||2,769||$63.66||$176,274.54|| |
|4/17/2014||Catherine Szyman||VP||Sell||29,420||$58.79||$1,729,601.80||21,602|| |
|4/9/2014||Richard Kuntz||VP||Sell||2,512||$60.98||$153,181.76||104,736|| |
|4/1/2014||Gary Lee Ellis||CFO||Sell||4,246||$61.48||$261,044.08||174,955|| |
|3/28/2014||Christopher Oconnell||EVP||Sell||1,982||$60.39||$119,692.98||120,652|| |
|3/20/2014||Catherine Szyman||VP||Sell||14,979||$59.57||$892,299.03||21,542|| |
|3/14/2014||Omar Ishrak||CEO||Sell||10,000||$59.12||$591,200.00||607,192|| |
|3/10/2014||Neil Ayotte||VP||Sell||1,845||$59.64||$110,035.80||10,782|| |
|12/4/2013||Neil Ayotte||VP||Sell||1,729||$57.14||$98,795.06||10,850|| |
|9/13/2013||Omar Ishrak||CEO||Sell||10,000||$53.58||$535,800.00||611,713|| |
|8/26/2013||Catherine Szyman||VP||Sell||56,998||$52.60||$2,998,094.80||21,217|| |
|8/22/2013||H James Dallas||VP||Sell||32,332||$53.19||$1,719,739.08||59,141|| |
|8/21/2013||H James Dallas||VP||Sell||36,256||$52.82||$1,915,041.92||91,473|| |
|8/21/2013||Shirley Jackson||Director||Sell||8,033||$52.84||$424,463.72||24,943|| |
|7/11/2013||Christopher J Oconnell||EVP||Sell||30,429||$52.92||$1,610,302.68|| |
|7/11/2013||Gary Lee Ellis||CFO||Sell||32,602||$53.62||$1,748,119.24|| |
|7/11/2013||H James Dallas||VP||Sell||69,889||$53.72||$3,754,437.08|| |
|7/1/2013||H James Dallas||VP||Sell||20,579||$52.10||$1,072,165.90|| |
|6/26/2013||D Cameron Findlay||VP||Sell||75,042||$52.20||$3,917,192.40|| |
|6/19/2013||H James Dallas||VP||Sell||94,117||$52.74||$4,963,730.58|| |
|5/22/2013||Richard H Anderson||Director||Buy||4,800||$52.32||$251,136.00|| |
|5/10/2013||Jack W Schuler||Director||Sell||34,230||$48.24||$1,651,255.20|| |
Medtronic (NYSE MDT) News Headlines
Medtronic (NYSE:MDT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Medtronic (NYSE:MDT) Income Statement, Balance Sheet and Cash Flow Statement
Medtronic (NYSE MDT) Stock Chart for Friday, March, 16, 2018